期刊
BIOMOLECULES
卷 13, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/biom13050850
关键词
FTO; SNP; m6A; cardiovascular diseases
The FTO gene, identified through a genome-wide association study, is strongly associated with the risk of cardiovascular diseases. FTO is not only the first obesity-susceptibility gene but also the first N-6-methyladenosine demethylase, indicating its role in m6A modification. By modulating RNA function through m6A demethylation, FTO plays a pivotal role in the initiation and progression of cardiovascular diseases and holds promise as a potential therapeutic target.
The fat mass and obesity-associated (FTO) gene was the first obesity-susceptibility gene identified through a genome-wide association study (GWAS). A growing number of studies have suggested that genetic variants of FTO are strongly associated with the risk of cardiovascular diseases, including hypertension and acute coronary syndrome. In addition, FTO was also the first N-6-methyladenosine (m6A) demethylase, suggesting the reversible nature of m6A modification. m6A is dynamically deposited, removed, and recognized by m6A methylases, demethylases, and m6A binding proteins, respectively. By catalyzing m6A demethylation on mRNA, FTO may participate in various biological processes by modulating RNA function. Recent studies demonstrated that FTO plays a pivotal role in the initiation and progression of cardiovascular diseases such as myocardial fibrosis, heart failure, and atherosclerosis and may hold promise as a potential therapeutic target for treating or preventing a variety of cardiovascular diseases. Here, we review the association between FTO genetic variants and cardiovascular disease risk, summarize the role of FTO as an m6A demethylase in cardiovascular disorders, and discuss future research directions and possible clinical implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据